

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that all resolutions as set out in the EGM Notice dated 12 August 2025 were duly passed at the EGM held on 29 August 2025.

RESULTS OF THE EGM

Reference is made to the notice of extraordinary general meeting (the “**EGM Notice**”) and the circular (the “**Circular**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), both dated 12 August 2025. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

The board of directors (the “**Board**”) is pleased to announce that all resolutions as set out in the EGM Notice were duly passed by way of poll at the extraordinary general meeting (the “**EGM**”) held on 29 August 2025.

As at the date of the EGM, the Company had 2,133,900,000 shares in issue including 697,500,000 domestic shares and 1,436,400,000 H shares. Shareholders of the Company holding a total of 664,995,000 shares of the Company were entitled to attend and vote for or against all the resolutions set out in the EGM Notice by way of poll at the EGM. There were no shares entitling the shareholders of the Company to attend and vote only against any of the resolutions at the EGM.

Details of the poll result in respect of resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTIONS		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
1.	To approve the adoption of the share award scheme of the Company	664,995,000 shares 100%	0 shares 0%	664,995,000 shares
2.	To approve the adoption of the Service Provider Sublimit (as defined in the share award scheme of the Company)	664,995,000 shares 100%	0 shares 0%	664,995,000 shares

The description of the resolutions are by way of summary only. The full text appears in the EGM Notice.

As more than half of the votes present at the EGM either in person or by proxy were cast in favor of the above ordinary resolutions numbered (1) to (2), these resolutions were duly passed as ordinary resolutions.

Ms. Sun Li as the executive director, Mr. He Xin and Ms. Li Xueying as the non-executive directors and Mr. Wang Yongkang, Mr. Tu Xiangzhen and Ms. Gao Chun as the independent non-executive directors attended the EGM.

RSM China CPA LLP (容誠會計師事務所(特殊普通合夥)), an independent external accountants firm acted as the scrutineer for the purpose of vote-taking at the EGM.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the People's Republic of China
29 August 2025

As at the date of this announcement, the executive director of the Company is Sun Li; the non-executive directors of the Company are He Xin, Li Ximing and Li Xueying; the independent non-executive directors of the Company are Tu Xiangzhen, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.